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Background: A sympathetic shift in heart rate variability (HRV) from high to lower
frequencies may be an early signal of deterioration in a monitored patient. Most chronic
heart failure (CHF) patients receive β-blockers. This tends to obscure HRV observation by
increasing the fast variations. We tested which HRV parameters would still detect the
change into a sympathetic state.
Methods and results: ®β-blocker (Carvedilol ) treated CHF patients underwent a protocol
of 10min supine rest, followed by 10min active standing. CHF patients (NYHA Class II–IV)
n = 15, 10m/5f, mean age 58.4 years (47–72); healthy controls n = 29, 18m/11f, mean age
62.9 years (49–78). Interbeat intervals (IBI) were extracted from the finger blood pressure
wave (Nexfin®). Both linear and non-linear HRV analyses were applied that (1) might be
able to differentiate patients from healthy controls under resting conditions and (2) detect
the change into a sympathetic state in the present short recordings.
Linear: mean-IBI, SD-IBI, root mean square of successive differences (rMSSD), pIBI-50
(the proportion of intervals that differs by more than 50ms from the previous), LF, HF, and
LF/HF ratio.
Non-linear: Sample entropy (SampEn), Multiscale entropy (MSE), and derived: Multiscale
variance (MSV) and Multiscale rMSSD (MSD). In the supine resting situation patients
differed from controls by having higher HF and, consequently, lower LF/HF. In addition their
longer range (τ = 6 − 10) MSE was lower as well. The sympathetic shift was, in controls,
detected by mean-IBI, rMSSD, pIBI-50, and LF/HF, all going down; in CHF by mean-IBI,
rMSSD, pIBI-50, and MSD (τ = 6 − 10) going down. MSD6–10 introduced here works as
a band-pass filter favoring frequencies from 0.02 to 0.1Hz.
Conclusions: In β-blocker treated CHF patients, traditional time domain analysis
(mean-IBI, rMSSD, pIBI-50) and MSD6–10 provide the most useful information to detect
a condition change.
Keywords: intensive care, home monitoring, heart rate variability, time domain analysis, frequency domain
analysis, entropy
INTRODUCTION
Heart rate variability (HRV) analysis has seen an increasing inter-
est since the early work of B.McA. Sayers in the 1970’s (Hyndman
et al., 1971), picking up speed since the 1980’s (Akselrod et al.,
1981; Baselli et al., 1987; deBoer et al., 1987). However, these anal-
ysis techniques still have not made it to the bedside, probably due
to the fact that equipment manufacturers do not offer standard
solutions in ECG-monitors to provide intricate HRV-data. Only
recently, some HRV-analysismethods have sneaked into the clinic
Abbreviations: BMI, body mass index; CHF, chronic heart failure; HF, high fre-
quency; HRV, heart rate variability; IBI, interbeat interval; ICU, Intensive Care
Unit; LF, low frequency; MSD, multiscale root mean square of successive dif-
ferences; MSE, Multi-Scale Entropy; MSV, multiscale variance; PVC, premature
ventricular contraction; rMSSD, root mean square of successive differences of IBI’s;
pIBI-50, proportion of pairs of successive IBI’s that differed by more than 50ms;
SampEn, sample entropy; SD-IBI, standard deviation of interbeat intervals; VLF,
very low frequency.
by a “stealth” method, hidden in algorithms that give a general-
ized “alert value” to a patient condition, based on observation of
a series of vital parameters (Clark et al., 2012; Lee et al., 2012;
Morris et al., 2007).
In the present study we tried a clinical approach to a prob-
lem that has received little attention in biomedical literature. It
has been fairly well-established that chronic heart failure patients
(CHF) have different HRV patterns compared to matched healthy
controls (Saul et al., 1988; Casolo et al., 1989). However, many
of those patients will be on β-blocker therapy, which has a
strong influence on both HR and HRV (Coumel et al., 1991;
Pousset et al., 1996; Mortara et al., 2000; Kubo et al., 2005).
Under these circumstances HRV has been shown to improve
toward normal (Mortara et al., 2000; Lin et al., 2001), a fact
that might mask an underlying developing disease status. We
therefore tested which HRV-analysis technique might be able to
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give early warning when there is a “slipping of” in the sympa-
thetic direction of the autonomic balance. To test this we used
recordings in CHF patients who went from supine to upright,
as a simple model to reduce vagal outflow to the heart and
induce generalized sympathetic activation. For this study we had
a set of 21 recordings in CHF-patients on Carvedilol® treatment
that has been fully described earlier (Truijen et al., 2011). In
view of the practical applicability in situations where a diagno-
sis should be available after a short period of recording only,
we were wondering if the 10min in supine posture followed
by 10min upright that we had were sufficient to answer two
questions:
1. Is there still a distinction health/disease when comparing the
supine recordings in β-blocker treated CHF patients to those
from matched, healthy controls?
2. Can HRV-analysis demonstrate an intra-individual shift
toward a more sympathetic state when comparing the upright
to the supine recording, even in this group of β-blocker treated
patients?
The first question is of importance for a quick triage of patients,
the second to detect a deterioration of a patient’s health before a
“normal” alarm would sound.
We decided to test a number of obvious linear measures, from
the time domain: mean-IBI (interbeat interval), SD-IBI (standard
deviation), rMSSD (root mean square of successive differences of
IBI’s), pIBI-50 (proportion of pairs of successive IBI’s that differ
by more than 50ms) and from the frequency domain: LF, HF and
LF/HF (Low Frequency around 0.1Hz, High Frequency, i.e., res-
piratory frequency, mostly around 0.25Hz, and their quotient).
In view of earlier studies where the use of short recordings for
non-linear analysis has been analyzed (Batchinsky et al., 2009;
Lake andMoorman, 2011; Leistedt et al., 2011; Turianikova et al.,
2011), we decided to use SampEn [sample entropy (Richman and
Moorman, 2000)] and Multiscale Entropy (MSE; Costa et al.,
2002). The latter method computes entropy over progressively
coarser grained versions of the original series. As a by-product we
considered the variances (Multiscale variance or MSV) and mul-
tiscale root mean square of successive differences (MSD) of those
newly constructed series as well.
A successful analysis method or combination of methods
should be able to do the triage (Question 1) as well as detect
the sympathetic shift (Question 2) within the limits of the 20min
recordings that were available.
METHODS
STUDY POPULATION
Patients
The patient recordings had been made in the study that has exten-
sively been described in (Truijen et al., 2011). In short: 21 CHF
patients (NY Heart Assoc. classification II–IV) participated in a
study that was directed to discrimination of β-blocker sensitivity
depending on the specific β2-receptor subtype that was present in
the patient. In a double-blind cross-over design they received the
non-selective β-blocker Carvedilol® (Eucardic, Roche, Mijdrecht,
Netherlands) or the selective metoprolol succinate (Selokeen
ZOC, AstraZeneca, Zoetermeer, Netherlands) as β-blocker for
6 weeks. Both drugs were titrated to equipotent dosages, addi-
tionally checked by resting heart rate. Since recordings made
under Carvedilol showed fewer extrasystoles and other rhythm
disturbances, we have restricted our study to the recordings
made after 6 weeks on this drug. It should be mentioned
here that Carvedilol is known to also have α1-blocking prop-
erties, without intrinsic sympathetic activity (Eggertsen et al.,
1984).
Patients had given their written informed consent after study
approval by the local Ethics committee. Due to problems with
too frequent premature ventricular contractions and erroneous
blood pressure tracings, 6 out of the original 21 patient recordings
(Truijen et al., 2011) under Carvedilol had to be rejected. This left
15 CHF patients for the present study, 10/5 (male/female), age
58.4 ± 6.5 (mean ± SD), BMI 27.4 ± 6.0.
Healthy control subjects
Subjects had been recruited by advertisement and selected to
match the patient group by gender, age and β2-receptor sub-
type. They were in good health, free of cardiovascular disease,
non-smokers. After written, informed consent 34 subjects partic-
ipated. Due to technical problems in the recordings and 2 cases
of near-syncope in the stand-test, 5 out of the original 34 con-
trol recordings had to be rejected. This left 29 (18/11, m/f), age
62.9 ± 7.3 BMI 26.1 ± 4.2 for analysis. There are no significant
differences in age and BMI distribution between healthy controls
and CHF patients.
MEASUREMENTS AND DATA PREPROCESSING
Continuous non-invasive blood pressure was measured from
a finger by the volume-clamp technique. A Nexfin® (BMEYE,
Amsterdam, Netherlands) hemodynamic monitor was used with
instantaneous display of reconstructed upper arm blood pressure,
heart rate, pulse contour derived cardiac output and systemic vas-
cular resistance. This enabled propermonitoring during the stand
test. To prevent hydrostatic errors the hand was held at heart level
in both positions by a sling around the neck.
Patients and controls underwent a test protocol which
included blood draws for clotting factors in the supine position
as described earlier (Truijen et al., 2011). Then they rested for at
least 20min before actively standing up. They remained standing
for another 10min. From the Nexfin computed data we only anal-
ysed IBI values for the present study, measured to an accuracy of
5ms (200Hz sample rate of A/D conversion).
In view of dysrhythmias like PVC’s, other rhythm disturbances
and, occasionally,movement artifacts that were present in the IBI-
recordings, they had to be pre-processed before analyses could
be performed. We used a two-step spike-removal procedure. First
we established the global mean value IBImean-glb of the whole set
(supine or upright), and substituted any IBIi outside the range
80–120% of IBImean-glb by that value. Next, a 10-beat window
would slide over the recording, replacing any newly added IBIj
outside the 80–120% range around the IBImean-local by the value
of the local mean. The first step deletes sharp spikes globally, mak-
ing it easier for the second step which is required to preserve
continuity of the time series.
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CALCULATION OF HRV PARAMETERS
Linear methods
Since we derived heart periods from blood pressure recordings
rather than from an ECG, we cannot call themNN-intervals (nor-
mal to normal) since, strictly spoken, we have no information
on the origin of the heartbeat, whether it originates from the
sinus node or from some other pacemaking site in the heart.
Although all patients underwent a test-ECG just prior to the
present recording, where normal sinus rhythm had been estab-
lished, we will use themore general term “IBI” (interbeat interval)
instead.
After data pre-processing as described above we calculated
mean-IBI, SD-IBI, rMSSD, pIBI-50 (the proportion of intervals
that differs by more than 50ms from the previous) following the
usual methods (Task Force of the European Society of Cardiology,
and the North American Society of Pacing and Electrophysiology,
1996). We chose a period of at least 5min stable recording for
both the supine and upright periods. Of the upright recording
a period of 2min after the standing up maneuver was skipped,
to allow for the first transient in blood pressure and heart rate
to disappear. This left a period of maximally 8min upright to be
included in the computations.
For the frequency analysis we used the IBI data set without
interpolation, putting the average interbeat interval as spacing
between heart beats (deBoer et al., 1984). After removal of a lin-
ear trend and Hanning-windowing we applied a digital Fourier
transform (Matlab®) rather than FFT. Thismethod can be applied
to an arbitrary number of data points without the need of zero-
padding until a power of two has been reached. LF, HF, and LF/HF
ratio were computed after integration of the spectral curve from
0.04 to 0.15Hz for LF and from 0.15 to 0.4Hz for HF. The values
were reduced to normalized units by division by the total variance
(Task Force, 1996).
Non-linear methods: SampEn and MSE
The calculation of MSE has been fully described in (Costa
et al., 2005). It is the sample entropy (SampEn) (Richman and
Moorman, 2000) of consecutively coarser grained time series Y
constructed from the original time series X:{x1, . . . , xi, . . . , xN}
by a scale factor of τ.
The coarse-graining procedure is the first step to compute
MSE, as well asMSV andmultiscale successive differences (MSD).
By taking τ consecutive values together, the original signal is pro-
gressively “smoothed” andmore and more beat-to-beat “noise” is
averaged out. This process is visualized in Figure 1 and formalized
in formula 1:
y(τ)j =
1
τ
jτ∑
i= (j − 1)τ+ 1
xi, 1 ≤ j ≤ N/τ. (1)
This describes a set of consecutively more coarse-grained time
series, [y(τ)] from the series X, where τ is the scale factor. Next, the
SampEn (Richman andMoorman, 2000) of each time series[y(τ)]
is computed, resulting in MSE. SampEn is a measure of the prob-
ability that a sequence of m consecutive data points will not
remain similar (within a given tolerance r) at the next point in
the data set. A high SampEn value implies low regularity, i.e.,
FIGURE 1 | Schematic diagram of the process of coarse-graining. This
is a representative ∼10min heart rate recording from a healthy volunteer in
supine position. From top to bottom tau = 1,2,5,10. X-scale: item number
in the series; Y-scale: (averaged) duration of heart periods in seconds.
few repetitions of the same pattern. Details on how to calculate
SampEn can be found in references (Richman and Moorman,
2000; Costa et al., 2002; Xinnian et al., 2006).
In short, MSE aims to measure the complexity of the system.
In a totally random sequence, SampEn will decrease to zero with
increasing τ; in a sequence that has been generated by a system
with some degree of complexity, like heart rate over time, it tends
to find a stable non-zero value.
Linear extension: MSV and MSD
We also computed a side-product of the coarse-graining pro-
cess, i.e., the (multiscale) variance (MSV) and multiscale rMSSD
(MSD) of the newly constructed series Y(τ). We reasoned that
these might show in a simple way the variability of heart rate at
medium-scale time-intervals.
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STATISTICS
All computations were done by use of SPSS®. After testing for
normality, comparisons between groups were done by pairwise
testing using Student’s t-test or Mann–Whitney u-test where
appropriate. For the change to a sympathetic state within one sub-
ject, we used the computed supine value to normalize the upright
value. The resulting quotient upright/supine was then linearized
by a log-transformation before statistical testing.
To compensate for the multiple comparisons we adapted the
test magnitude alpha by applying the Bonferroni–Holm correc-
tion. This will lead to a value of alpha smaller than the 0.05 that
we considered significant. The corrected alpha is mentioned in
the tables along with the computed exact p-value. This allows
the reader to judge the significance of observed changes, taking
into account the type I/type II error as well as the biological sig-
nificance of the change (Cabin and Mitchell, 2000; Nakagawa,
2004).
RESULTS
COMPARISON CHF PATIENTS vs. HEALTHY CONTROLS
Table 1 gives an overview of the chosen 11 HRV parameters in
patients and control subjects in the supine posture. It is remark-
able that the mean supine heart rates, pIBI-50 and rMSSD in the
two groups are equal despite the β-blockade in the patients. Total
variability as expressed by SD-IBI is lower in CHF, although not
statistically significant. HF as short term variability index is higher
in CHF, but this may well be due to the β-blockade (Goldsmith
et al., 1997; Witte and Clark, 2008). As a consequence LF/HF is
significantly lower in CHF as well.
To further analyze the internal structure of the variability we
computed, first, the MSE-curves for τ = 1–10, results shown in
Figure 2A. At τ = 1 SampEn in CHF and controls are equal
(Table 1). For values of τ above 3 the curve of the CHF-patients
falls below that of the healthy controls. However, a large overlap
exists. To emphasize the longer range interactions rather than the
short-term variability (Ho et al., 2011) we integrated the val-
ues for τ from 6 to 10, resulting in the MSE6−10 number in
Table 1. The variances of the coarse grained distributions for
increasing τ are depicted by the MSV as shown in Figure 2B.
Average MSV in CHF is lower than that in controls for all val-
ues of τ; we averaged the value for τ = 6–10 as MSV6−10 in
Table 1. Except for τ = 1 the same holds true for the rMSSD of
the coarse grained distributions, expressed as MSD in Figure 2C
and averaged to one value from τ = 6 to 10 in Table 1. Both
MSV6−10 and MSD6−10 are lower in CHF than in controls, how-
ever, in view of the wide distribution of the numbers, taking the
Bonferroni–Holm corrected alpha and the magnitude of the dif-
ference into account, we do not consider these differences biolog-
ically significant. The same cannot be said for MSE6−10: although
the number fails to meet the Bonferroni–Holm corrected alpha
(p = 0.05/9 = 0.006), yet in view of the narrow distribution
and the exact p-value of 0.015 we do consider this difference
significant.
SYMPATHETIC SHIFT IN CONTROL SUBJECTS: UPRIGHT vs. SUPINE
POSTURE
We computed the 11 parameters again for the upright condi-
tion, and expressed the upright value as fraction of the individual
supine one. For statistical testing the values have been log-
transformed, to obtain values which follow a normal distribution
with mean = 0 if the supine and upright values are equal. The
averages and p-values are shown in Table 2.
As to be expected, mean-IBI has significantly decreased, i.e.,
heart rate goes up on standing. All short-term variability mea-
sures go down as well: rMSSD, pIBI-50 and HF. The increase in
LF did not reach statistical significance; LF/HF increased in line
with the decreased HF. SampEn and the coarse grained measures,
MSE6−10, MSV6−10, and MSD6−10 did not change.
Table 1 | Parameter comparison between control subjects and CHF patients in 10-min supine posture.
Parameter (units) Control CHF p-value Bonferroni–Holm
corrected alpha
Deemed
significant
meanIBI (ms) 1002 ± 158 951 ± 120 0.281 0.02 no
SD-IBI (ms) 38.0 (21.8–87.2) 32.4 ± 15.7 0.090 0.01 no
rMSSD (ms) 25.7 (12.1–125.4) 27.8 ± 14.5 0.795 0.05 no
pIBI-50 (proportion) 0.04 (0.00–0.84) 0.03 (0.00–0.26) 0.586 0.025 no
LF (n.u.) 0.19 ± 0.07 0.13 ± 0.08 0.025* 0.007 no
HF (n.u.) 0.25 (0.09–0.72) 0.52 ± 0.23 0.000# 0.005 yes
LF/HF 1.06 ± 0.73 0.36 ± 0.36 0.000# 0.005 yes
SampEn 1.51 ± 0.37 1.69 ± 0.32 0.152 0.0125 no
MSE6−10 1.57 ± 0.21 1.35 ± 0.39 0.015* 0.006 yes
MSV6−10 (ms2) 870 (303.4–4210.4) 554 (3.0–1880.8) 0.046* 0.008 no
MSD6−10 (ms) 24.5 (13.6–75.2) 19.6 ± 11.0 0.016* 0.006 no
If data are normal distributed, the value is as mean ± std and the Student t-test is applied; if non-normal distributed, the value is as median (minimum–maximum)
and the Mann–Whitney U test is applied. Before Bonferroni–Holm correction, *p < 0.05; #p < 0.01; n.u. = normalized units (power in the respective bands is
normalized by division by total variance). The values of MSE, MSV, and MSD are computed by averaging over the 5 highest tau values: sum[MSE(tau = 6:10)]/5,
sum[MSV(tau = 6:10)]/5, sum[MSD(tau = 6:10)]/5. The column “deemed significant” gives the interpretation of the authors, taking the p-value, corrected alpha and
the biological significance into account; cf. text.
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FIGURE 2 | MSE, MSV, and MSD curves: comparison between control
subjects and CHF patients in supine posture. (A) MSE; (B) MSV; (C)
MSD. Fat (blue) line: control healthy subjects; dotted (red) line: CHF
patients. Tau from 1 to 10. The curves represent mean values with ±1
standard deviation. CHF patients have lower MSE, MSV, and MSD than
healthy subjects for tau above 2.
SYMPATHETIC SHIFT IN CHF PATIENTS: UPRIGHT vs. SUPINE POSTURE
Generally speaking, the sympathetic change in CHF-patients
followed the same pattern as in healthy control subjects, without
statistically significant differences between the two groups.
However, there were a few notable within-group exceptions, as
shown in Table 2.
In the patients mean-IBI decreased significantly, so did
rMSSD, pIBI-50, but none of the frequency analysis mea-
sures. Of the non-linear and coarse-grained parameters only
MSD6−10 decreased significantly, the other ones did not change
appreciably.
ABSOLUTE POWER RESULTS FROM FOURIER ANALYSIS
Fourier analysis of HRVmay be analyzed in many ways; we chose
to look at the individual normalized powers of LF and HF and
the LF/HF quotients. However, if the underlying (absolute) data
are very much changed by the intervention (standing up in this
case) these numbers may be misleading. Therefore, we checked
the absolute powers and in addition those in the VLF band
(very low frequency band: from the lowest observed frequency
in the 5–10min recording to 0.04Hz). The results are given in
Table 3. No significant changes in total power or power in the
various bands with standing were detectable. These might have
invalidated the above analyses.
DISCUSSION
The present computer-based post-hoc study tried to establish the
numbers that could aid in fast diagnosis of a β-blocker treated
patient’s “slipping off” into a more sympathetic state. We chose
a stand-test as model for this condition; no one can stand very
well for 10min without sympathetic system involvement in view
of the induced drop in blood pressure at the level of the carotid
sinuses and the relative hypovolemia that is observed by pressure
sensitive receptors in the low-pressure area (atria, lungs) (Borst
et al., 1982; Ten Harkel et al., 1993).
We reasoned that patients on a β-blocker, when remotely mon-
itored or admitted to an intensive care unit for acute exacerbation
of symptoms, might pose additional challenges to a monitoring
system that would incorporate HRV-measures in an intelligent
alarm. Beta-blockers have a tendency to increase short term HRV
as well as total background variability as it may be observed in
the low to very low frequency ranges (Goldsmith et al., 1997;
Aronson and Burger, 2001; Bullinga et al., 2005). Moreover, the
additional α1-blocking properties of Carvedilol may lead to less
apparent blood pressure waves when sympathetic arousal takes
place. This property has been pointed out as instrumental in not
lowering HR as much as do other β-blockers (Stoschitzky et al.,
2001), as compensation for the decreased systemic resistance that
it provokes (Ferrua et al., 2005).
In line with our initial suppositions we found that in the
supine resting state the CHF-patients differed from the healthy
control subjects by showing equal HR with almost equal SD-
IBI, but significantly higher HF variability, therefore lower LF/HF
ratio. Furthermore, the patients had slightly lower values for
MSE6−10, MSV6−10, and MSD6−10. In our view this is mirror-
ing the increased beat-to-beat variability due to the β-blocker
together with a slightly increased sympathetic activation. When
going to the upright posture the control subjects displayed most
of the expected changes: increased HR, decreased rMSSD, pIBI-
50, HF, increased LF/HF, but not an increased LF, probably due
to the large variance in this measure. MSE6−10, MSD6−10, or
MSV6−10 did not record a change. When it came to the CHF-
patients in upright posture the parameters that did show up
as useful were HR (increased), rMSSD, pIBI-50 and MSD6−10
(decreased). None of the other parameters would indicate a
shift into a sympathetic state. Our results in the healthy con-
trol group tally well with those of Turianikova et al. (2011) who
recently published a comparable orthostasis study. Exception is
our lack of results for MSE6−10; in comparison we would have
expected a definite increase. However, we studied subjects around
63 years of age, the earlier study had subjects around 20 years
of age.
A few notes should be made; the most important one being
that almost all HRV is vagally mediated: both the fast beat-to-beat
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Table 2 | Control subjects and CHF patients: normalized parameters (=upright/supine).
Normalized Parameter =
(upright/supine)
Control subjects p-value CHF patients p-value
Mean IBI 0.84 ± 0.06 0.000# 0.90 ± 0.06 0.00003#
SD-IBI 0.98 ± 0.36 0.253 0.92 ± 0.44 0.130
rMSSD 0.72 ± 0.28 0.00001# 0.69 ± 0.24 0.0003#
pIBI-50 0.36 (0.00–1.75) 0.000# 0.15 (0.00–2.55) 0.009#
LF 1.60 ± 1.65 0.123 1.19 ± 0.92 0.635
HF 0.89 ± 0.55 0.019* 1.00 ± 0.71 0.279
LF/HF 2.87 ± 3.36 0.008# 2.01 ± 2.91 0.723
SampEn 0.96 ± 0.30 0.066 0.94 ± 0.29 0.199
MSE6−10 1.02 ± 0.18 0.256 0.98 (0.31–1.63) 0.609
MSV6−10 1.39 ± 1.17 0.989 1.55 ± 2.42 0.540
MSD6−10 1.01 ± 0.48 0.314 0.76 ± 0.22 0.001#
If data are normal distributed, the value is as mean ± sd and a one-sample t-test is applied; if non-normal distributed, the value is as median (minimum–maximum)
and a Wilcoxon signed-rank test is applied. Normalized parameters are calculated as: (value of upright)/(value of supine) for every individual. After log-transformation
a one-sample t-test has been used to test the deviation from zero (i.e., upright value = supine value); *p < 0.05; #p < 0.01 (within-group differences for upright to
supine); the values of MSE, MSV, and MSD are as in Table 1: sum[MSE(tau = 6:10)]/5, sum[MSV(tau = 6:10)]/5, sum[MSD(tau = 6:10)]/5.
Table 3 | Total power and power in the various bands: VLF, LF, HF; supine values compared to upright.
Parameter (ms2) Control subjects [median (min–max)] CHF patients
Supine Upright Supine Upright
Total power 1445 (474–7602) 1437 (226–9627) 1162 (44–2974) 677 (59–2823)
VLF 770 (271–4477) 934 (133–5147) 265 (1–2106) 322 (0–2086)
LF 243 (34–1804) 235 (43–3185) 116 (6–646) 75 (2–537)
HF 344 (44–4902) 189 (49–1295) 464 (27–1561) 238 (57–1036)
In view of the non-normal distributions of absolute powers the medians and ranges are given.
No within-group significant changes from supine to upright can be demonstrated due to the large variability.
changes and the slower waves that may be riding on underlying
blood pressure variations. As long as heart rate is in the vagal
range, for humans below (120 − 0.6 × age) (Karemaker et al.,
1989), most variations in HR will, as first guess, mainly come
from changes in vagal activity. That is not to say that the sympa-
thetics play no role in HRV, their contribution can be found both
in the underlying blood pressure variability and the longer-range
variations in heart rate. These slower variations, to be observed
over the course of minutes to hours, may influence both HR and
BP at the same time, via central and peripheral mechanisms. In
analysis techniques that aim at this “system complexity” it has
become established that stable estimates may only be found when
thousands of heart beats are incorporated, an order of magnitude
requiring at least some 4 h observation. This is a requirement that
is impractical for straightforward clinical monitoring. Although
4 h of data may become available in any patient on the moni-
tor, a deterioration of condition should be signaled earlier than
after 4 h.
In recent years the literature on HRV analysis methods has
been reviewed for various areas of application. Rajendra Acharya
et al. (2006) gave a more or less complete overview of methodolo-
gies that are applied, from time domain to frequency domain to
non-linear analysis methods. Generally speaking, the main disad-
vantages of the latter are the large number of data required and
the sensitivity to baseline shift and noise of some of the meth-
ods. In 2007 Maestri et al. (2007) reviewed the use of non-linear
indices of HRV for CHF patients. Many were highly corre-
lated to classical linear indices; only two (families of) analysis
methods gave independent prognostic information, i.e., empiri-
cal mode decomposition and symbolic dynamics. We considered
these not practical for our purpose. Again in 2009 Buccelletti
et al. (2009) noted that techniques like power law (fractal)
analysis or detrended fluctuation analysis were less practical in
the prognosis of myocardial infarction patients than entropy
directed methods in view of the number of required heart beats.
In the present study we have, therefore, restricted our analy-
sis to SampEn and MSE, being the most promising ones for
our application. We looked at scale factors 6–10 for MSE, sup-
ported by a recent study by Ho et al. (2011) who had noticed
that in CHF patients on β-blockade values of τ = 6 and up
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were insensitive to this therapy when used as predictors of
mortality.
In short, the most reliable HRV parameters to early detect a
patient’s “slipping off” into a sympathetic state are those that
indicate so-called vagal withdrawal, i.e., the disappearance of
short-term variability and the loss of longer term “jumpiness”
as shown by the decreased MSD6−10. These changes will occur
even before heart rate goes up into a definite sympathetic region,
where all vagal efferent traffic is silenced. The newer parameters
like SampEn or MSE have no use here, at least not in the present
group of patients who use β-blockers. A study by Batchinsky et al.
(2009) has shown that SampEn can make a difference for triage
in emergency care, even when only short recordings are available.
Interestingly, the newly introduced parameter MSD6−10 seems
to do a good job as well, detecting both the sympathetic shift
and the difference between healthy controls and CHF-patients.
This computes the “jumpiness” or rMSSD of coarse grained
averages over 6–10 adjacent beats. This is not a non-linear param-
eter like MSE or SampEn, but one that is derived from the
intermediate coarse grained series constructed for the compu-
tation of MSE. In that same vein we computed the variances of
these series, which showed some promise in the controls-CHF
comparison of Table 1, but failed to show a sympathetic shift
(in Table 2).
rMSSD has peculiar properties, acting as a high-pass filter to
the original heart rate signal. It has been proven (Berntson et al.,
2005) that “classical” rMSSD captures the same frequency range
as the HF band in frequency analysis does, roughly between 0.2
and 0.45Hz. However, it is biased by the prevailing heart rate and
is sensitive to lower frequencies as well. By extending the algo-
rithm to progressively more coarse grained series of heart periods
we have, with MSD6−10, constructed a combination of a low-
pass filter (the coarse-graining process, cf. Figure 1) followed by
a high-pass filter. Building on the earlier study into the rMSSD
filter properties one may extrapolate that the number represented
byMSD6−10 will favor frequencies between 0.02 and 0.07Hz (i.e.,
0.2/10 and 0.45/6 as 3dB points), thus mainly spanning the LF-
band and slightly lower, as illustrated in Figure 3, the result of
a simulation like in the Berntson study. It should be noted that
these filter characteristics are dependent on the prevailing heart
rate. In the present simulation, as in our study, we assumed an
average heart rate of 60/min, 1 s intervals. This problem of scaling
by heart rate is one that is omnipresent in MSE-studies, although
very seldom mentioned.
IN CONCLUSION
For patients on β-blockers only the gradual disappearance
of short-term variability, as measured by traditional methods
rMSSD and pIBI-50, proved a reliable indicator of a shift to a
sympathetic state. The newly introduced MSD6−10—jumpiness
in coarse grained beat series—shows some promise here as well.
HRV analysis cannot work in clinical monitoring without tak-
ing HR-active medication into account; without β-blockade more
parameters might be useful, notably SampEn and frequency anal-
ysis may carry useful information for the clinician. The best
application for these measures is probably their use in intelligent
FIGURE 3 | Band-pass filter characteristics of MSD6−10. The algorithm
has been applied to model-generated beat-series with additional noise. A
simplified model of baroreflex control has been used as in deBoer et al.,
1987 to generate the intervals. Average heart period around 1000ms. A
modulating “respiratory” frequency was forced with periods from 3 to
120s. The values for MDS6−10 have been normalized to the peak–peak
amplitudes of the forced oscillations (Berntson et al., 2005).
monitoring, where the clinician is not bothered with the numbers
and their intricacies, but just with the condition changes that are
shown by analysis of HRV along with other vital parameters.
LIMITATIONS
This study was conducted in a small number of relatively healthy
CHF-patients: they had been stable on their medication before
entering the study. The circumstances for patients admitted
to the ICU for an acute cardiac condition may be quite dif-
ferent. Therefore, this study should be extended to real-life
ICU-recordings and to larger groups of patients before definite
conclusions about the usefulness of the present HRV-measures
may be reached.
In a standard ICU-setting one would turn to the ECG-monitor
for more accurate heart period detection than was possible here.
The use of a 200Hz sampled BP-recording limits the accuracy
to ∼5ms, whereas normally at least 1ms should be obtainable.
Therefore, some measures that came out as rather insensitive
now, like SampEn or MSE for low values of τ might per-
form better then. For “classical” MSE the present recordings
were too short anyway, reason why we limited the τ (coarse
graining parameter) to 10 rather than going to 20. At τ =
10 we have in a 10min recording about 60 points for the
coarse grained series. Since our τ-MSE curves reached stable
levels for the data sets that we used, we considered this choice
appropriate.
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